AlloSure™ Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Piper Jaffray Remains Bullish on CareDx (CDNA) Following Presentation of AlloSure Performance
June 14, 2016 9:07 AM EDTPiper Jaffray maintained an Overweight rating and $6.00 price target on CareDx, Inc (NASDAQ: CDNA) following the company's presentation of its DART clinical trial. Piper Jaffray would describe DART's first look data as solid with AlloSure a significantly better predictor of kidney health than creatinine.
Analyst William Quirk... More
Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
June 14, 2016 7:20 AM EDTMizuho Securities maintained a Buy rating on CareDx, Inc (NASDAQ: CDNA), and cut the price target to $8.00 (from $12.00) mainly due to share dilution from the Allenex acquisition. The deal transforms CDNA into a comprehensive transplant test provider, adding pre-transplant solutions, and increases the... More
